Amneal Pharmaceuticals, Inc. $AMRX Stake Lessened by State of Alaska Department of Revenue

State of Alaska Department of Revenue lessened its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 38.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 45,479 shares of the company’s stock after selling 28,866 shares during the quarter. State of Alaska Department of Revenue’s holdings in Amneal Pharmaceuticals were worth $915,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP raised its holdings in Amneal Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after acquiring an additional 81,546 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Amneal Pharmaceuticals by 72.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after acquiring an additional 1,069,400 shares during the last quarter. Congress Asset Management Co. lifted its stake in Amneal Pharmaceuticals by 94.7% in the third quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock worth $30,701,000 after acquiring an additional 741,577 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Amneal Pharmaceuticals in the second quarter worth approximately $17,573,000. Finally, Principal Financial Group Inc. grew its holdings in Amneal Pharmaceuticals by 527.9% during the 1st quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock worth $12,089,000 after acquiring an additional 817,652 shares in the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMRX has been the topic of a number of recent analyst reports. The Goldman Sachs Group reissued a “buy” rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Oppenheimer started coverage on shares of Amneal Pharmaceuticals in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $27.00 price objective on the stock. UBS Group reaffirmed a “buy” rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Leerink Partners assumed coverage on shares of Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $23.00 price objective for the company. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and set a $22.00 target price on shares of Amneal Pharmaceuticals in a research note on Wednesday, August 26th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Insiders Place Their Bets

In related news, Director John Kiely sold 50,000 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the sale, the director directly owned 210,252 shares of the company’s stock, valued at $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Nikita Shah sold 146,403 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the sale, the executive vice president directly owned 253,390 shares of the company’s stock, valued at $4,436,858.90. The trade was a 36.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Trading Up 1.8%

AMRX opened at $20.20 on Thursday. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. Amneal Pharmaceuticals, Inc. has a one year low of $9.99 and a one year high of $21.17. The company has a market cap of $6.45 billion, a P/E ratio of 23.07, a PEG ratio of 2.33 and a beta of 1.22. The business’s 50-day simple moving average is $18.68 and its 200-day simple moving average is $16.36.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.06. The firm had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.95 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.